The power
of PRALUENT

Powerful LDL-C reduction with 2 levels of efficacy

View PRALUENT efficacy

 

Who is
PRALUENT for?

Patients you often see in clinical practice

View PRALUENT patient types

 

Dosing
flexibility

Flexible dosing options with powerful efficacy

Learn more about PRALUENT dosing

 

Savings and
long-term support

Comprehensive assistance with cost, coverage, and more

Get started today

 

Need help getting patients started on PRALUENT? Learn how iAssist may simplify access or Connect Now with a Reimbursement Specialist

Dosing Information

  • The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks

*Formulary data are provided by Managed Markets Insights & Technology, LLC (MMIT) and are current as of April 1, 2016. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage.2

Reference:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.